Celldex Therapeutics Inc. (NASDAQ:CLDX) shares, rose in value on Thursday, 06/23/22, with the stock price up by 5.53% to the previous day’s close as strong demand from buyers drove the stock to $26.14.
Actively observing the price movement in the last trading, the stock closed the session at $24.77, falling within a range of $24.45 and $26.31. The value of beta (5-year monthly) was 2.78. Referring to stock’s 52-week performance, its high was $57.20, and the low was $19.85. On the whole, CLDX has fluctuated by -11.75% over the past month.
With the market capitalization of Celldex Therapeutics Inc. currently standing at about $1.18 billion, investors are eagerly awaiting this quarter’s results, scheduled for Mar 28, 2022 – Apr 01, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.45, which is expected to increase to -$0.44 for fiscal year -$1.96 and then to about -$2.21 by fiscal year 2023. Data indicates that the EPS growth is expected to be -19.50% in 2023, while the next year’s EPS growth is forecast to be -12.80%.
According to the average forecast, sales growth in current quarter could jump down -37.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $1.32 million, representing a decrease of -71.60% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that CLDX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of CLDX currently trading nearly 9.97% and -7.69% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 53.84, while the 7-day volatility ratio is showing 8.52% which for the 30-day chart, stands at 8.62%. Furthermore, Celldex Therapeutics Inc. (CLDX)’s beta value is 2.62, and its average true range (ATR) is 1.97.
Data on historical trading for Celldex Therapeutics Inc. (NASDAQ:CLDX) indicates that the trading volumes over the past 3 months, they’ve averaged 600.30K. According to company’s latest data on outstanding shares, there are 46.74 million shares outstanding.
The stock has fallen by -32.35% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CLDX stock heading into the next quarter.